The disclosure pertains to antibodies that bind A-beta oligomers and methods of making and using said antibodies.

The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an amyloid beta peptide, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease.

The invention relates to antibodies, antibody fragments and binding agents that specifically recognizes oligomeric A that is resistant to denaturation by SDS but does not bind monomeric, fibrillar or other oligomeric forms of A that are generated in vitro.

The invention relates to a compound for use for inducing apoptosis in a cancerous cell, wherein said compound is selected from the group consisting of ApoO, a variant or a fragment thereof, their mixtures, and a vector encoding for said ApoO, variant or fragment thereof. The invention further relates to a compound for use for treating a pathophysiological situation, wherein said compound is an inhibitor of the ApoO activity or of the ApoO gene expression.

Apparatuses and methods are provided. Some methods may include providing a substrate to a processing chamber, the substrate having a first material adjacent to and covering a surface of a second material, modifying a layer of the first material by flowing a first process gas onto the substrate and thereby creating a modified layer of the first material, removing the modified layer of the first material by flowing a second process gas onto the substrate, and converting, when the surface of the second material is uncovered via removal of the modified layer, the surface to a converted layer of the second material by flowing a third process gas onto the substrate, in which the first and second process gases are less reactive with the converted layer than with the first material and the second material.

In certain embodiments compositions are provided that comprise a pentapeptide comprising the formula: C.sup.1-X.sup.2-X.sup.3-X.sup.4-C.sup.5 where C.sup.1 and C.sup.5 are independently selected cysteines or cysteine analogues, or other amino acids with sidechains suitable for cyclization, where the cysteines or cysteine analogs are attached to each other by a linkage that does not comprise X.sup.2, X.sup.3, and X.sup.4; where X.sup.2, X.sup.3, and X.sup.4 are independently selected amino acids; and the peptide, when administered to a cell alters APP signaling and/or switches APP processing from aberrant to normal. The compositions mitigate amyloid plaque formation.

The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.

The present invention relates to SAP-Fc fusion proteins and methods of treating amyloid related diseases.

The present invention relates to a peptide, and to a pharmaceutical composition and a heterocomplex comprising the peptide. Furthermore, the present invention relates to the peptide, the pharmaceutical composition, or the heterocomplex for use in a method of preventing or treating Alzheimer's disease and/or for use in a method of preventing or treating type 2 diabetes. The present invention further relates to the peptide, the pharmaceutical composition, or the heterocomplex for use in a method of diagnosing Alzheimer's disease and/or for use in a method of diagnosing type 2 diabetes. The present invention also relates to a kit for the in vitro or in vivo detection of amyloid fibrils or aggregates, or for the diagnosis of Alzheimer's disease and/or type 2 diabetes in a patient. Moreover, the present invention relates to the use of the peptide or of the heterocomplex in an in vitro assay for the detection of monomeric islet amyloid polypeptide (LAPP), monomeric A.sub.40 (.sub.42), amyloid fibrils, or amyloid aggregates.

Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.